Skip to content
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Hematology

Ghosal hematodiaphyseal dysplasia: A Patient Guide

At a Glance

Ghosal hematodiaphyseal dysplasia (GHDD) is an inherited TBXAS1-related condition that thickens the long bones and scars the bone marrow, causing anemia of variable severity. Off-label corticosteroids may improve blood counts in some people, but there is no established cure.

Ghosal hematodiaphyseal dysplasia (GHDD) is an exceptionally rare, inherited condition that acts as a bridge between two seemingly different systems in the body: the skeletal system and the blood-forming marrow. Because GHDD can be diagnosed in childhood or adulthood, this guide is written for both patients and caregivers. For a person with GHDD, the body undergoes a unique process where the long bones of the arms and legs become unusually thick and dense, while the marrow inside those bones—the “factory” where blood is made—develops scarring that can lead to severe anemia [1][2].

At the biological heart of this condition is a change in the TBXAS1 gene. This gene normally helps regulate the balance of inflammatory signals in the body, but when it is not functioning correctly, it is thought to cause a “backup” of certain substances that drive chronic inflammation. This inflammation is the proposed mechanism behind the disease, signaling the bones to over-build and the bone marrow to develop the fibrosis (scarring) that crowds out healthy red blood cells and platelets [3][4].

One of the most striking features of GHDD is how differently it can appear from one person to the next. The severity of the condition is highly variable; while some children develop profound anemia and bone changes early in life, others—even within the same family—may have such mild symptoms that they are not diagnosed until adulthood. This means that while the genetic cause is the same, your experience with GHDD will be unique [2][5].

Despite the rarity of GHDD, there are management strategies. Because the condition is driven by inflammation, doctors have found that certain off-label treatments, particularly corticosteroids, may produce a substantial hematologic response in some patients by “calming” the inflammatory signals. These treatments have been reported to improve blood counts and reduce the need for transfusions, though responses, duration, dose, and effects on bone changes are variable and there is no established cure [5][6].

Living with GHDD means building a partnership with a specialized care team, typically led by pediatric or adult hematologists and bone specialists who can monitor both the blood and the skeletal changes. While the rarity of the diagnosis can feel isolating, understanding the underlying inflammatory driver allows your medical team to move beyond managing symptoms and toward treatments that address the condition.

Note: GHDD is genetically confirmed but clinically variable. Treatment decisions are individualized, and this guide does not replace the treating hematologist or local emergency instructions.

Common questions in this guide

What is Ghosal hematodiaphyseal dysplasia?
Ghosal hematodiaphyseal dysplasia is a very rare inherited condition that makes the long bones unusually thick and dense. Scarring in the bone marrow can interfere with blood-cell production, leading to anemia and sometimes low platelet counts.
What causes GHDD?
GHDD is linked to a change in the TBXAS1 gene. The altered gene is thought to disrupt inflammatory signals, which may drive excess bone buildup and scarring in the bone marrow.
What symptoms can GHDD cause?
Symptoms vary widely from person to person. They may include anemia-related fatigue, bone pain, and thickening of the long bones; some people become seriously ill in childhood, while others have mild symptoms that are recognized in adulthood.
Can corticosteroids help treat GHDD?
Corticosteroids are off-label treatments that may improve blood counts and reduce the need for transfusions in some people with GHDD. The dose, duration of benefit, response, and effect on bone changes vary, and there is no established cure.
How should GHDD be monitored?
Monitoring usually involves a coordinated team that includes a hematologist and a bone specialist. The team can follow blood counts, anemia-related concerns, and changes in the skeleton while adapting care to the person's symptoms and treatment response.
What can be done if corticosteroids do not work for GHDD?
If corticosteroids do not help or their benefit does not last, ask the hematologist about individualized next-step options. The best plan depends on the person's blood counts, bone findings, symptoms, and response to earlier treatment.

Get notified when new evidence is published on Ghosal hematodiaphyseal dysplasia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (6)
  1. 1

    Characterization of Novel Variants in P2YRY12, GP6 and TBXAS1 in Patients with Lifelong History of Bleeding.

    Zamora-Cánovas A, Marín-Quílez A, Díaz-Ajenjo L, et al.

    Biomolecules 2025; (15(12)) doi:10.3390/biom15121639.

    PMID: 41463295
  2. 2

    Novel compound heterozygous variants of TBXAS1 presenting with Ghosal hematodiaphyseal dysplasia treated with steroids.

    Kim SY, Ing A, Gong S, et al.

    Molecular genetics & genomic medicine 2021; (9(3)):e1494 doi:10.1002/mgg3.1494.

    PMID: 33595912
  3. 3

    Nonsteroidal anti-inflammatory drugs as a targeted therapy for bone marrow failure in Ghosal hematodiaphyseal dysplasia.

    Brown TJ, Barrett N, Meng H, et al.

    Blood 2023; (141(13)):1553-1559 doi:10.1182/blood.2022018667.

    PMID: 36574346
  4. 4

    Ghosal Hematodiaphyseal Dysplasia: A Case Report With Review of Genetically Confirmed Cases.

    Dikme G, Karkucak M, Topçu FS, Bozkurt C

    Journal of pediatric hematology/oncology 2026; (48(5)):e189-e195 doi:10.1097/MPH.0000000000003208.

    PMID: 42059562
  5. 5

    Ghosal Type Hematodiaphyseal Dysplasia.

    Jeevan A, Doyard M, Kabra M, et al.

    Indian pediatrics 2016; (53(4)):347-8 doi:10.1007/s13312-016-0851-y.

    PMID: 27156553
  6. 6

    Ghosal Hematodiaphyseal Dysplasia: A Case Report.

    Shakiba M, Shamsian S, Malekzadeh H, Yasaei M

    International journal of hematology-oncology and stem cell research 2020; (14(2)):127-129.

    PMID: 32461797

This guide about Ghosal hematodiaphyseal dysplasia is for informational purposes only and does not constitute medical advice. Your hematologist and bone specialist should guide diagnosis, monitoring, and treatment decisions.